PCM
RAPT

Pinz Capital Management’s RAPT Therapeutics RAPT Stock Holding History

Pinz Capital Management’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-29,781
Closed -$7.57M – 342
2021
Q2 		$7.57M Buy
+29,781
New +$5.56M 2.28% 10

Other funds holding RAPT

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PM
Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
KXA
KPCB XV Associates Menlo Park, California $35.8M AUM 57.59% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Pinz Capital Management's RAPT Position: Q3 2021 in Review

Pinz Capital Management sold out of RAPT Therapeutics (RAPT) in Q3 2021, closing a stake of 29,781 shares — an estimated $7.57M sold.

Pinz Capital Management first reported a position in RAPT in Q2 2021 and held it in 1 quarter. The position peaked at $7.57M in Q2 2021. 106 funds tracked by Wall St. Rank hold RAPT as of Q3 2021.

  • Pinz Capital Management reported no remaining RAPT Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Pinz Capital Management sold 29,781 RAPT Therapeutics shares in Q3 2021, an estimated $7.57M.
  • Pinz Capital Management first reported a position in RAPT Therapeutics in Q2 2021 and held it in 1 quarter.
  • Pinz Capital Management's RAPT Therapeutics position peaked at $7.57M in Q2 2021.
  • 106 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q3 2021.

Based on Pinz Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.